Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in

Review and 2022 Outlook in Letter to Shareholders

Fla., January 18, 2022 /PRNewswire/

- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),

a patient-centric biotechnology company, today released a letter to shareholders from Dr. Joseph Tucker, Chief Executive Officer of Enveric

Enveric Shareholders and Partners:

on 2021, I am both extremely impressed with all the accomplishments and progress made and humbled and energized to tackle the opportunities

that lie ahead. 2021 was a foundational year that set the stage for our Company by assembling a talented and expert team to execute our

strategy for the future. As we move forward in 2022, we find ourselves strategically positioned with a strengthened balance sheet, a

deep bench of experienced industry professionals, a platform for new drug discovery, a robust IP portfolio and a growing pipeline of

what we believe to be promising drug candidates. We are energized to engage with what I believe will be yet another transformative year

launched as a patient-centric biotechnology company, employing innovation and scientific leadership as core principles. Notable highlights

of September 30, 2021, we had $21 million in cash, no debt related to loans payable, and working capital of approximately $20 million,

enabling us to continue executing on our business plan.

foundation of Enveric's growth in 2022 will be built upon three pillars: our Drug Development pipeline, Drug Discovery

process, and Intellectual Property strategy.

the new company structure, strengthened by the foundational achievements in 2021 including the assembly of an expert team with the passion

and drive for drug development, I am confident in Enveric's ability to execute on our programs in 2022 and beyond.

behalf of the Enveric management team and Board of Directors, I thank you for your continued support of the company and I look forward

to providing you with further updates as our progress continues.

Executive Officer, Director

Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments

and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's

robust pipeline supports drug discovery efforts and clinical development programs to enable potential commercialization of effective

treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.

Statement Regarding Forward-Looking Statements

press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These

statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking

statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology

such as "plans", " expects" or "does not expect", "proposed", "is expected",

"budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates"

or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases

which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist

of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding

the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently

available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result

of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments;

the impact of the novel coronavirus (COVID-19) on Enveric's ongoing and planned clinical trials; the geographic, social and economic

impact of COVID-19 on Enveric's ability to conduct its business and raise capital in the future when needed; delays in planned

clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability

to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary

governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital

and to obtain such funding on commercially reasonable terms; Enveric's ability to manufacture product candidates on a commercial

scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and

scientists; and the ability to secure and enforce legal rights related to Enveric's products, including patent protection. A discussion

of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the

Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form

10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information,

future events or otherwise, except as required by law.

Pinto / Allison Soss

Strategic Communications